GetReal: from efficacy in clinical trials to relative effectiveness in the real world

Matthias Egger, a,b* Karel G. M. Moons, c,d Christine Fletcher e and GetReal Workpackage 4

The GetReal consortium ("incorporating real-life data into drug development") addresses the efficacy–
effectiveness gap that opens between the data from well-controlled randomized trials in selected patient
groups submitted to regulators and the real-world evidence on effectiveness and safety of drugs required
decision makers. Package 4 of GetReal develops evidence synthesis and modelling approaches to
generate the real-world evidence. In this commentary, we discuss how questions change when moving
from the well-controlled randomized trial setting to real-life medical practice, the evidence required to
answer these questions, the populations to which estimates will be applicable to and the methods and
data sources used to produce these estimates. We then introduce the methodological reviews written by
GetReal authors and published in Research Synthesis Methods on network meta-analysis (Efthimiou et al.,
2016), individual patient data meta-analysis (Debray et al., 2015) and mathematical modelling to predict Q3
drug effectiveness (Panayidou et al., 2016). The critical reviews of key methods are a good starting point
for the ambitious programme of work GetReal has embarked on. The different strands of work under
way in GetReal have great potential to contribute to making clinical trials research as relevant as it can
be to patients, caregivers and policy makers. Copyright © 2016 John Wiley & Sons, Ltd.

The randomized clinical trial is the most reliable study design to determine the efficacy and safety of drugs.
However, the clinical trials system has been described as “broken,” “in crisis” and “not fit for purpose”: many trials
do not achieve patient enrolment targets; spiralling costs and complex regulatory and monitoring requirements
prevent the conduct of others; and many completed trials do not answer clinically relevant questions or are not
applicable to everyday medical practice but are driven by commercial considerations (DeVita, 2008; Vickers,
2014; Loudon et al., 2013). As a consequence, fewer trials that are relevant to patients, caregivers and policy
makers are carried out, and the evidence on the benefits and risks of drugs is becoming less reliable.

Several initiatives have been established in recent years to remedy this situation. In the USA, Duke University
and the Food and Drug Administration established CTTI, the Clinical Trials Transformation Initiative (Tenaerts
et al., 2014). CTTI’s mission is “to promote practices that will increase the quality and efficiency of clinical trials,”
with the aim to create a clinical trials system that is “patient centered and efficient, enabling reliable and timely
access to evidence-based prevention and treatment options.” The initiative has generated evidence and
formulated recommendations, for example, to streamline risk-based trial monitoring and the ethical review
process. Similarly, Oxford University in the UK, McMaster University in Canada and Duke have joined forces to form
the Sensible Guidelines Group to “rid clinical trials of undue bureaucracy, maximize patient safety, and improve
the efficiency of reaching valid conclusions from large multi-centre randomized studies” (Shurlock, 2013).

Launched in October 2013, “GetReal: Incorporating real-life data into drug development” of the European
Union’s Innovative Medicines Initiative is another important development to enhance the efficiency of
randomized trials and the quantification of effectiveness and safety of drugs in real-world medical practice.
GetReal is a public–private consortium consisting of academia, pharmaceutical companies, health technology
assessment agencies, regulators and patient organizations (GetReal consortium). GetReal addresses the

*Correspondence to: Matthias Egger, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
E-mail: egger@ispm.unibe.ch

©2016 John Wiley & Sons, Ltd.
“efficacy–effectiveness gap” (Eichler et al., 2011) that opens between the data from well-controlled randomized studies in selected patient groups submitted to regulators and the real-world evidence (RWE) on effectiveness and safety of drugs, required by decision makers. Decisions on whether a new drug should be made available in a national health system or reimbursed by social insurance requires evidence on its relative effectiveness and safety compared with established treatments and the wider implications including costs of introducing a new therapy. Ideally, such evidence should be made available to regulatory and health technology assessment agencies before the drug enters the market.

GetReal aims to develop methods and tools that support the generation of RWE on the relative effectiveness of new drugs that could inform decision-making before the drug is launched. The GetReal consortium works with stakeholders to

(i) develop a framework for the acceptability of RWE for estimating the effectiveness of new medicines (workpackage 1),
(ii) study the scientific validity of RWE, including non-randomized study designs, and analytical approaches and drivers of effectiveness (workpackage 2),
(iii) examine the challenges and possible solutions to performing pragmatic trials earlier in the development process, in particular prelaunch or peri-launch (workpackage 3),
(iv) develop evidence synthesis and modelling approaches to generate RWE, based on combination of both randomized and observational study data (workpackage 4)

Workpackage 4 will be of particular interest to the readership of Research Synthesis Methods. In workpackage 4, we examine how estimates of the relative efficacy of drugs in clinical trial populations, their relative effectiveness in real world populations and their relative effectiveness in the real world of a healthcare systems can best be obtained, using data from phase II/III clinical trials and from real-world clinical databases and registries. Table 1 summarizes the questions asked, moving from the randomized clinical trial setting to real-life medical practice, the evidence required to answer these questions, the populations to which estimates will be applicable to and the methods and data sources used to produce these estimates.

We use case studies of the treatment of chronic diseases, for example, schizophrenia, depression and rheumatoid arthritis, to examine different methodological approaches for combining both randomized and observational study data, both using aggregate study data and using individual participant data. For example,

<table>
<thead>
<tr>
<th>Steps and questions</th>
<th>Outcomes of interest</th>
<th>Applicability to patient populations</th>
<th>Data sources</th>
<th>Methodology</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) How efficacious and safe is this drug?</td>
<td>Efficacy, safety</td>
<td>Typical patients included in clinical trials</td>
<td>Phase II/III randomised clinical trials</td>
<td>Clinical trials, standard meta-analysis</td>
<td>Study conditions</td>
</tr>
<tr>
<td>2) How efficacious and safe is this drug compared with alternative therapies?</td>
<td>Relative efficacy, relative safety</td>
<td>Typical patients included in clinical trials</td>
<td>Phase II/III randomised clinical trials</td>
<td>Network meta-analysis</td>
<td>Study conditions</td>
</tr>
<tr>
<td>3) How effective and safe is this drug compared with alternative therapies, in patients who will likely receive it post-launch?</td>
<td>Relative effectiveness, relative safety in predicted study populations</td>
<td>Patients predicted to receive the drug post-launch</td>
<td>Phase II/III randomised clinical trials, clinical databases and registries</td>
<td>Individual patient data network meta-analysis and meta-regression</td>
<td>Study conditions</td>
</tr>
<tr>
<td>4) How effective and safe is this drug compared with alternative therapies, in the patients who will likely receive it in the real world of a healthcare system?</td>
<td>Relative effectiveness, relative safety in predicted real-world populations</td>
<td>Patients predicted to receive the drug post-launch in a given healthcare system</td>
<td>Phase II/III randomised clinical trials, clinical databases and registries, expert opinion, patient preferences</td>
<td>Mathematical modelling</td>
<td>Real-world conditions</td>
</tr>
</tbody>
</table>
we use network meta-analysis approaches of aggregate study results to obtain estimates of relative efficacy from several randomized trials. One of the drugs in the network is, for the sake of the argument, designated as the “new kid on the block,” and the trials of this drug are assumed to be prelaunch, whereas the other drugs are assumed to be on the market. Subsequently, individual participant data (IPD) provided by the participating pharmaceutical companies and observational data from clinical databases and disease registries are combined to identify important factors that modify the drug’s relative effectiveness and to estimate its performance in patient populations that will likely receive the drug after launch. Of note, at this stage, the relative effectiveness of the drug continues to be estimated under randomized study conditions, rather than real-world conditions (Table 1).

Foreexample, adherence to treatments is implicitly assumed to correspond to that observed in the phase II/III trials. The next step is to account for the messy real world, where doctors decide who will receive the new drug, influenced by guidelines, patient characteristics and preferences, and other factors. In order to gauge relative effectiveness, these decisions need to be understood as well as the possible confounding factors that may be associated with the probability both of receiving the drug and of developing the outcome and the variables that may be associated with the treatment (but not with the outcomes) or of variables associated with outcomes (but not treatment). The likely adherence to the new drug and to the comparator drugs is also relevant. Empirical evidence on these factors will typically be scarce, or absent. Drawing directed acyclic graphs and in-depth discussions with clinicians are helpful to understand how the different variables are likely to interact and what predictive model might be most appropriate (Westreich and Edwards, 2015).

It is good practice first to critically review the methods and applications that will be important in a research programme, to gain an understanding of the relevant strengths and limitations. In this issue and a previous issue of the journal, GetReal investigators present reviews of common methods used for network meta-analysis (Efthimiou et al., 2016), IPD meta-analysis (Debray et al., 2015) and mathematical modelling to predict drug effectiveness (Panayidou et al., 2016). In their review of network meta-analysis methods, Efthimiou et al. summarize the key issues involved, including novel methods for measuring and detecting inconsistency in the network, dealing with effect modification, ways for adjusting for possible sources of bias and the reporting of the results of a network meta-analysis (Efthimiou et al., 2016). IPD meta-analysis is widely considered to be the gold standard in meta-analytic research, but in their review, Debray et al. stress that they are no panacea to the limitations of the included studies. Also, IPD meta-analyses are major undertakings, which cannot be performed ad hoc or on a shoe string, and their potential advantages, for example, the powerful investigation of interaction and subgroup effects, must be carefully weighed against the extra efforts involved (Debray et al., 2015). Finally, Panayidou and colleagues comprehensively searched for studies that predicted real-world effectiveness from randomized controlled trial data. Of note, they found only 12 articles and four modelling approaches, mainly Markov multistate models (Panayidou et al., 2016). Although most studies included sensitivity analyses, external validation was rarely performed.

The critical reviews of the key methodologies published in the Research Synthesis Methods are a good starting point for the ambitious programme of work the GetReal consortium has embarked on. The different strands of work under way in GetReal have great potential to contribute to making clinical trials research as relevant as it can possibly be to patients, caregivers and policy makers. Watch this space!

Acknowledgements

This work was conducted as part of the GetReal consortium. For further information, please refer to http://www.imi-getreal.eu. This commentary reflects the personal views of the authors. The authors are grateful to Georgia Salanti and Eva-Maria Didden for helpful comments on an earlier draft.

References

Loudon K et al. 2013. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose. Trials 14: 115.


Dear Author,

During the copyediting of your paper, the following queries arose. Please respond to these by annotating your proofs with the necessary changes/additions.

- If you intend to annotate your proof electronically, please refer to the E-annotation guidelines.
- If you intend to annotate your proof by means of hard-copy mark-up, please use the standard proofing marks. If manually writing corrections on your proof and returning it by fax, do not write too close to the edge of the paper. Please remember that illegible mark-ups may delay publication.

Whether you opt for hard-copy or electronic annotation of your proofs, we recommend that you provide additional clarification of answers to queries by entering your answers on the query sheet, in addition to the text mark-up.

<table>
<thead>
<tr>
<th>Query No.</th>
<th>Query</th>
<th>Remark</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td>AUTHOR: Please confirm that given names (red) and surnames/family names (green) have been identified correctly.</td>
<td></td>
</tr>
<tr>
<td>Q2</td>
<td>AUTHOR: Please check that authors and their affiliations are correct.</td>
<td></td>
</tr>
<tr>
<td>Q3</td>
<td>AUTHOR: Reference citations are not allowed in abstract section. Please reword texts (if necessary) and delete citations.</td>
<td></td>
</tr>
<tr>
<td>Q4</td>
<td>AUTHOR: Please update any ‘in press’ references if available.</td>
<td></td>
</tr>
<tr>
<td>Q5</td>
<td>AUTHOR: Reference “GetReal consortium, IMI GetReal - real-life data in drug development (n.d.)” is not cited in the text. Please indicate where it should be cited; or delete from the reference list.</td>
<td></td>
</tr>
<tr>
<td>Q6</td>
<td>AUTHOR: Please update any ‘in press’ references if available.</td>
<td></td>
</tr>
<tr>
<td>Q7</td>
<td>AUTHOR: Please provide the page range for Reference Tenaerts et al. (2014).</td>
<td></td>
</tr>
</tbody>
</table>
Required software to e-annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 7.0 or above). (Note that this document uses screenshots from Adobe Reader X)
The latest version of Acrobat Reader can be downloaded for free at: http://get.adobe.com/uk/reader/

Once you have Acrobat Reader open on your computer, click on the Comment tab at the right of the toolbar:

This will open up a panel down the right side of the document. The majority of tools you will use for annotating your proof will be in the Annotations section, pictured opposite. We’ve picked out some of these tools below:

1. Replace (Ins) Tool – for replacing text.

   Strikethrough text and opens up a text box where replacement text can be entered.

   How to use it
   - Highlight a word or sentence.
   - Click on the Replace (Ins) icon in the Annotations section.
   - Type the replacement text into the blue box that appears.

   ![Replace (Ins) Tool](image)

2. Strikethrough (Del) Tool – for deleting text.

   Strikethrough text and opens up a text box where replacement text can be entered.

   How to use it
   - Highlight a word or sentence.
   - Click on the Strikethrough (Del) icon in the Annotations section.

   ![Strikethrough (Del) Tool](image)

3. Add note to text Tool – for highlighting a section to be changed to bold or italic.

   Highlights text in yellow and opens up a text box where comments can be entered.

   How to use it
   - Highlight the relevant section of text.
   - Click on the Add note to text icon in the Annotations section.
   - Type instruction on what should be changed regarding the text into the yellow box that appears.

   ![Add note to text Tool](image)

4. Add sticky note Tool – for making notes at specific points in the text.

   Marks a point in the proof where a comment needs to be highlighted.

   How to use it
   - Click on the Add sticky note icon in the Annotations section.
   - Click at the point in the proof where the comment should be inserted.
   - Type the comment into the yellow box that appears.

   ![Add sticky note Tool](image)
USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION

5. **Attach File Tool** — for inserting large amounts of text or replacement figures.

How to use it
- Click on the Attach File icon in the Annotations section.
- Select the file to be attached from your computer or network.
- Select the colour and type of icon that will appear in the proof. Click OK.

6. **Add stamp Tool** — for approving a proof if no corrections are required.

How to use it
- Click on the Add stamp icon in the Annotations section.
- Select the stamp you want to use. (The Approved stamp is usually available directly in the menu that appears).
- Click on the proof where you’d like the stamp to appear. (Where a proof is to be approved as it is, this would normally be on the first page).

7. **Drawing Markups Tools** — for drawing shapes, lines and freeform annotations on proofs and commenting on these marks.

How to use it
- Click on one of the shapes in the Drawing Markups section.
- Click on the proof at the relevant point and draw the selected shape with the cursor.
- To add a comment to the drawn shape, move the cursor over the shape until an arrowhead appears.
- Double click on the shape and type any text in the red box that appears.

For further information on how to annotate proofs, click on the Help menu to reveal a list of further options: